Being able to use Hsp90 expression as a surrogate for TIL levels may allow for a way to extend the prognostication available to patients with ER+ breast tumors to patients with HER2+ or triple negative breast cancers. Here, ERBB2 is linked to triple-negative breast carcinoma.